Rapport Therapeutics (RAPP) FCF Margin (2026)
Rapport Therapeutics' (RAPP) quarterly FCF Margin came in at 65.74% in Q1 2026.
Rapport Therapeutics (RAPP) FCF Margin (2026) Analysis & Trends
Rapport Therapeutics (RAPP) has 1 years of FCF Margin data on file, last reported at 65.74% in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Rapport Therapeutics | 1.95 Bn | 1.95 Bn | - | -65.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -65.74% |